S3E3: The Future of Cancer Medicine with Dr. Jay Bradner, President of Novartis Institutes for BioMedical Research

In the last 20 years or so, many new cancer treatments have emerged that provide greater precision and targeting of cancer cells.Today, we have a better understanding of the genetic components of cancer.Through novel technology and cutting-edge science, we’re now able to understand how the accumulation of molecular alterations in the genome leads to the coding of proteins that can promote uncontrolled cell division.New treatments are emerging at the genetic and molecular level, along with novel approaches to targeting the new microenvironment that cancers create.On this episode of Theory and Practice, we explore the future of cancer medicine, and there’s no better leader to turn to for that discussion than Dr. Jay Bradner. Since 2016, he’s been president of the Novartis Institutes for BioMedical Research, where he leads the discovery and development of life-changing therapies to benefit patients.Theory and Practice is a presentation of GV and Google AI.This season we'll dive deep into the languages of life through explorations of the "dark genome", genome editing, protein folding, the future of aging, and more.Hosted by Anthony Philippakis (Venture Partner at GV) and Alex Wiltschko (Staff Research Scientist with Google AI), Theory and Practice opens the doors to the cutting edge of biology and computer science through conversations with leaders in the field.